| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2692-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-50356-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-52639-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-11921-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB110-93606-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-123SS | |||
![Immunohistochemistry-Paraffin: ErbB2/Her2 Antibody (4D5-8 (trastuzumab)) - Chimeric [NBP2-52639] - Immunohistochemical Anti-erbB-2 (Her-2/neu) staining of paraffin embedded human breast tissue using the rabbit-chimeric version of 4D5-8 (trastuzumab) (NBP2-52639). Primary antibody incubation with NBP2-52639 was carried out at 4 ug/ml for 30 minutes. Samples were then incubated with an anti-rabbit IgG HRP secondary antibody for 20 mins followed by DAB (3,3'-diaminobenzidine), and counter-staining with haemotoxylin. Weak membrane staining exclusively of ductal epithelial cells may be observed. Recommended concentration, 4-6 ug/ml.](http://images.novusbio.com/fullsize/ErbB2-Her2-Antibody-4D5-8-trastuzumab-Chimeric-Immunohistochemistry-Paraffin-NBP2-52639-img0001.jpg "Immunohistochemistry-Paraffin: ErbB2/Her2 Antibody (4D5-8 (trastuzumab)) - Chimeric [NBP2-52639] - Immunohistochemical Anti-erbB-2 (Her-2/neu) staining of paraffin embedded human breast tissue using the rabbit-chimeric version of 4D5-8 (trastuzumab) (NBP2-52639). Primary antibody incubation with NBP2-52639 was carried out at 4 ug/ml for 30 minutes. Samples were then incubated with an anti-rabbit IgG HRP secondary antibody for 20 mins followed by DAB (3,3'-diaminobenzidine), and counter-staining with haemotoxylin. Weak membrane staining exclusively of ductal epithelial cells may be observed. Recommended concentration, 4-6 ug/ml.")
![Western Blot: PDGFR alpha Antibody (OTI1C10) - Azide and BSA Free [NBP2-73303] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PDGF R alpha.](http://images.novusbio.com/fullsize/PDGFR-alpha-Antibody-OTI1C10-Azide-and-BSA-Free-Western-Blot-NBP2-73303-img0001.jpg "Western Blot: PDGFR alpha Antibody (OTI1C10) - Azide and BSA Free [NBP2-73303] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PDGF R alpha.")
![Western Blot: MAP3K15 Antibody (OTI1G10) - Azide and BSA Free [NBP2-72588] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY MAP3K15.](http://images.novusbio.com/fullsize/MAP3K15-Antibody-OTI1G10-Azide-and-BSA-Free-Western-Blot-NBP2-72588-img0001.jpg "Western Blot: MAP3K15 Antibody (OTI1G10) - Azide and BSA Free [NBP2-72588] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY MAP3K15.")
![Western Blot: VRK1 Antibody (OTI2C9) - Azide and BSA Free [NBP2-74855] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY VRK1.](http://images.novusbio.com/fullsize/VRK1-Antibody-OTI2C9-Azide-and-BSA-Free-Western-Blot-NBP2-74855-img0001.jpg "Western Blot: VRK1 Antibody (OTI2C9) - Azide and BSA Free [NBP2-74855] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY VRK1.")
![Western Blot: ROR1 Antibody (OTI3D11) - Azide and BSA Free [NBP2-73931] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY ROR1 .](http://images.novusbio.com/fullsize/ROR1-Antibody-OTI3D11-Azide-and-BSA-Free-Western-Blot-NBP2-73931-img0001.jpg "Western Blot: ROR1 Antibody (OTI3D11) - Azide and BSA Free [NBP2-73931] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY ROR1 .")
![Western Blot: PRAK Antibody (OTI5E1) - Azide and BSA Free [NBP2-73594] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PRAK.](http://images.novusbio.com/fullsize/PRAK-Antibody-OTI5E1-Azide-and-BSA-Free-Western-Blot-NBP2-73594-img0001.jpg "Western Blot: PRAK Antibody (OTI5E1) - Azide and BSA Free [NBP2-73594] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY PRAK.")
![Immunohistochemistry-Paraffin: TGF-beta RI/ALK-5 Antibody (RM0016-3A11) [NBP2-11921] - Parrafin lung and kidney sections from LPS treated mice using anti ALK5 antibody.](http://images.novusbio.com/fullsize/TGF-beta-RI-ALK-5-Antibody-RM0016-3A11-Immunohistochemistry-Paraffin-NBP2-11921-img0002.jpg "Immunohistochemistry-Paraffin: TGF-beta RI/ALK-5 Antibody (RM0016-3A11) [NBP2-11921] - Parrafin lung and kidney sections from LPS treated mice using anti ALK5 antibody.")
![Immunohistochemistry-Paraffin: EphA7 Antibody (6E1) [NB110-93606] - The Kidney tissue samples from the Folic Acid induced kidney injury model were fixed using 4% PFA at 4C for overnight and embeded in paraffin. 4um section was sublected to IHC with NB110-93606](http://images.novusbio.com/fullsize/EphA7-Antibody-6E1-Immunohistochemistry-Paraffin-NB110-93606-img0001.jpg "Immunohistochemistry-Paraffin: EphA7 Antibody (6E1) [NB110-93606] - The Kidney tissue samples from the Folic Acid induced kidney injury model were fixed using 4% PFA at 4C for overnight and embeded in paraffin. 4um section was sublected to IHC with NB110-93606")
![Immunohistochemistry-Paraffin: Mer Antibody (3D07) [NB110-94148] - Mer immunohistochemistry staining of paraffin sections of mouse lung and spleen tissues from LPS exposed animals.](http://images.novusbio.com/fullsize/Mer-Antibody-3D07-Immunohistochemistry-Paraffin-NB110-94148-img0003.jpg "Immunohistochemistry-Paraffin: Mer Antibody (3D07) [NB110-94148] - Mer immunohistochemistry staining of paraffin sections of mouse lung and spleen tissues from LPS exposed animals.")